ClinicalTrials.gg
Not yet recruitingNCT07943208Updated Nov 17, 2026

Gluteus Maximus Transfer for Hip Abductor Insufficiency Following Total Hip Arthroplasty

An interventional study of Gluteus Maximus Transfer in Hip Abductor Insufficiency Following Total Hip Arthroplasty, sponsored by Ain Shams University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Hip abductor insufficiency is a challenging complication following total hip arthroplasty (THA). It may result from damage to the abductor muscles or tendons, particularly the gluteus medius and minimus, and can lead to persistent hip pain, muscle weakness, a positive Trendelenburg sign, and impaired walking ability.

Gluteus maximus transfer is a surgical procedure used to restore the function of the hip abductor mechanism in patients with severe abductor insufficiency. This study aims to evaluate the clinical and functional outcomes of gluteus maximus transfer in patients who develop abductor insufficiency following total hip arthroplasty.

The study will assess postoperative improvements in hip function, abductor strength, gait, pain, and patient-reported functional outcomes, as well as the occurrence of postoperative complications. The hypothesis is that gluteus maximus transfer can provide meaningful functional improvement in appropriately selected patients with persistent abductor insufficiency following total hip arthroplasty.

02

Conditions studied

  • Hip Abductor Insufficiency Following Total Hip Arthroplasty

Keywords

  • Gluteus Maximus Transfer
  • Total Hip Arthroplasty
  • Hip Abductor Insufficiency
  • Abductor Mechanism Reconstruction
  • Trendelenburg Gait
  • Gluteus Medius
  • Gluteus Minimus
03

In context

Lead sponsor

Ain Shams University is the lead sponsor of 1,956 studies on the registry; 431 are open to participants now.

Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

**Inclusion Criteria**

  1. Adult patients aged 18 years or older.
  2. Patients who underwent primary or revision total hip arthroplasty.
  3. Patients with symptomatic hip abductor insufficiency following total hip arthroplasty.
  4. Clinical evidence of abductor mechanism deficiency, including abductor weakness, positive Trendelenburg sign, or gait disturbance.
  5. Patients with irreparable or functionally deficient hip abductor mechanism considered suitable for gluteus maximus transfer.
  6. Availability of preoperative and postoperative clinical and functional assessment data.

**Exclusion Criteria**

  1. Active periprosthetic joint infection at the time of the planned procedure.
  2. Neurological disorders significantly affecting hip abductor function or gait.
  3. Severe gluteus maximus muscle dysfunction or insufficiency that precludes transfer.
  4. Severe medical comorbidities contraindicating surgery.
  5. Inadequate clinical follow-up or missing essential outcome data.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Gluteus Maximus Transfer

    Patients with hip abductor insufficiency following total hip arthroplasty undergoing gluteus maximus transfer for reconstruction of the deficient hip abductor mechanism.

    Procedure: Gluteus Maximus Transfer

Interventions

  • ProcedureGluteus Maximus Transfer

    Surgical transfer of the gluteus maximus muscle to reconstruct the deficient hip abductor mechanism in patients with persistent abductor insufficiency following total hip arthroplasty. The procedure aims to improve hip abductor function, pelvic stability, gait, and overall functional outcomes.

06

What researchers measure

Primary outcomes

  1. Change in Hip Abductor Muscle Strength

    Assessment of hip abductor muscle strength before and after gluteus maximus transfer using manual muscle testing according to the Medical Research Council (MRC) grading scale (0-5).

    Time frame: Preoperative assessment and 12 months postoperatively.

Secondary outcomes

  1. Functional Outcome - Harris Hip Score

    Change in Harris Hip Score from preoperative baseline to 12 months postoperatively to assess hip pain and function.

    Time frame: preoperative baseline to 12 months postoperatively

  2. Trendelenburg Sign

    Assessment of the presence or absence of Trendelenburg sign during clinical examination before and 12 month after surgery.

    Time frame: preoperative and 12 month postoperative

  3. Pain Assessment

    Change in hip pain intensity measured using the Visual Analog Scale (VAS).

    Time frame: preoperative and 12 months postoperative

  4. Postoperative Complications

    Documentation of postoperative complications, including persistent abductor weakness, infection, dislocation, wound complications, and revision surgery.

    Time frame: during the period of follow up 12 months postoperative

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Nov 2026, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2026
First posted
Nov 17, 2026
StartEst.
Oct 30, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07943208
Responsible party
Ahmed Saeed Younis (DR, Ain Shams University) — Principal investigator
First posted
Nov 17, 2026
Start date
Oct 30, 2026 (estimated)
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion